The TTPH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TTPH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The TTPH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View TTPH Detailed Price Forecast - CNN Money||View TTPH Detailed Summary - Google Finance|
|View TTPH Detailed Summary - Yahoo! Finance||View TTPH Stock Research & Analysis - Zacks.com|
|View TTPH Trends & Analysis - Trade-Ideas||View TTPH Major Holders - Barrons|
|View TTPH Call Transcripts - NASDAQ||View TTPH Breaking News & Analysis - Seeking Alpha|
|View TTPH Annual Report - CompanySpotlight.com||View TTPH OTC Short Report - OTCShortReport.com|
|View TTPH Fundamentals - TradeKing||View TTPH SEC Filings - Bar Chart|
|View Historical Prices for TTPH - The WSJ||View Performance/Total Return for TTPH - Morningstar|
|View the Analyst Estimates for TTPH - MarketWatch||View the Earnings History for TTPH - CNBC|
|View the TTPH Earnings - StockMarketWatch||View TTPH Buy or Sell Recommendations - MacroAxis|
|View the TTPH Bullish Patterns - American Bulls||View TTPH Short Pain Metrics - ShortPainBot.com|
|View TTPH Stock Mentions - StockTwits||View TTPH Stock Mentions - PennyStockTweets|
|View TTPH Stock Mentions - Twitter||View TTPH Investment Forum News - Investor Hub|
|View TTPH Stock Mentions - Yahoo! Message Board||View TTPH Stock Mentions - Seeking Alpha|
|View Insider Transactions for TTPH - SECform4.com||View Insider Transactions for TTPH - Insider Cow|
|View TTPH Major Holdings Summary - CNBC||View Insider Disclosure for TTPH - OTC Markets|
|View Insider Transactions for TTPH - Yahoo! Finance||View Institutional Holdings for TTPH - NASDAQ|
|View TTPH Stock Insight & Charts - FinViz.com||View TTPH Investment Charts - StockCharts.com|
|View TTPH Stock Overview & Charts - BarChart||View TTPH User Generated Charts - Trading View|
Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Posted on Thursday July 12, 2018
Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Tetraphase's Compensation Committee of the Board of Directors approved, pursuant to NASDAQ Listing Rule 5635(c)(4), the grant of inducement equity awards in the form of stock options to four new employees to purchase an aggregate of 60,000 shares of Tetraphase's common stock. The options were granted as an inducement equity awards outside Tetraphase's 2013 Stock Incentive Plan and were made as an inducement material to four new employee’s acceptance of employment with Tetraphase. The stock options have exercise prices equal to the closing price of Tetraphase's common stock on July 13, 2018.
Breakfast Technical Briefing on Tetraphase Pharma and Three Other Additional Biotech Stocks
Posted on Thursday July 12, 2018
LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on TTPH sign up now at www.wallstequities.com/registration. Companies in the Biotechnology industry primarily use living organisms or molecular and cellular techniques to provide chemicals, food, and services that meet human needs.
Detailed Research: Economic Perspectives on Tetraphase Pharmaceuticals, Tech Data, Southern National Bancorp of Virginia, Esterline Technologies, Myers Industries, and Hersha Hospitality Trust — What Drives Growth in Today's Competitive Landscape
Posted on Thursday June 21, 2018
NEW YORK, June 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tetraphase ...
Tetraphase Pharmaceuticals Announces Data from a Pooled Analysis of IGNITE1 and IGNITE4 Phase 3 Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections at the ASM Microbe 2018 Annual Meeting
Posted on Monday June 11, 2018
Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, recently reported data on eravacycline, which is currently under review by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of complicated intra-abdominal infections (cIAI), as well as data for TP-6076, its second-generation candidate targeting MDR Gram-negative bacteria, which is currently in phase 1 clinical testing. “For the first time, we are sharing a pooled analysis of our IGNITE1 and IGNITE4 studies of eravacycline and are pleased to show that favorable clinical and microbiological responses were observed for eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including those demonstrating resistant phenotypes and genotypes such as MDR and extended spectrum beta-lactamase (ESBL) production,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase.